<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03832153</url>
  </required_header>
  <id_info>
    <org_study_id>20181028</org_study_id>
    <nct_id>NCT03832153</nct_id>
  </id_info>
  <brief_title>Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes</brief_title>
  <acronym>PGCA-ACS</acronym>
  <official_title>Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HELLENIC CENTER FOR MARINE RESEARCH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Research and Technology Hellas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction with ST elevation (STEMI) is one of the leading causes of&#xD;
      mortality. Although the presence of thrombus in STEMI patients has been linked to adverse&#xD;
      outcomes, routine thrombus aspiration has not been proven effective. A potential explanation&#xD;
      could be that patients with STEMI should be risk-stratified. Thus, a more personalized&#xD;
      approach in treating these patients is stressfully required. This proposal aims to establish&#xD;
      the required interdisciplinary infrastructure for developing a risk-stratification model by&#xD;
      implementing clinical, laboratory and angiographic data with molecular knowledge obtained by&#xD;
      using innovative technologies, such as data from nano/micro-Computed tomography and&#xD;
      circulating microRNAs. Two hundred consecutive patients with STEMI undergoing thrombus&#xD;
      aspiration will be enrolled in the study and will be followed-up for one year for Major&#xD;
      Adverse Cardiac and Cerebrovascular events (MACCE). The proposed approach will shed light on&#xD;
      the pathophysiological mechanisms and broaden the investigator's understanding of the complex&#xD;
      cellular and molecular interactions in the STEMI setting that, along with clinical&#xD;
      parameters, affect patient outcomes. Furthermore, it will enable the identification of&#xD;
      certain circulating micro-RNAs as cardiovascular disease biomarkers and it will help&#xD;
      clinicians to better stratify the cardiovascular and cerebrovascular risk of patients with&#xD;
      STEMI. As part of the work, important characteristics of aspirated thrombi will be assessed&#xD;
      for the first time (such as volume, density and shape) and will be linked to patient&#xD;
      outcomes. All this information will be incorporated into one in-vitro model, which will be&#xD;
      developed using bioprinting and microfluidics methodologies. The in-vitro model will&#xD;
      facilitate: (i) the in-depth exploration of the pathophysiological mechanisms in patients&#xD;
      with STEMI; and (ii) the therapeutic optimization of innovative nanocarriers/nanomedicines&#xD;
      with thrombolytic efficacy. Clearly, the study improves personalized cardiovascular medicine&#xD;
      approaches, by considering individual patient clinical assessment in a way that empowers the&#xD;
      precision in diagnosis and therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    LACK OF FUNDING&#xD;
  </why_stopped>
  <start_date type="Actual">January 20, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fold changes of differentially-expressed microRNA from peripheral blood from patients suffering from STEMI (measured in log2 scale)</measure>
    <time_frame>12 months</time_frame>
    <description>The expression profiles of the total number of microRNAs that exist in the peripheral blood of patients suffering from STEMI will be analyzed using Next Generation Sequencing (NGS). Blood samples collected from the patients will be used to extract microRNAs through the application of suitable microRNA isolation kit (miRNeasy Serum/Plasma kit). Following, the miRNA library construction will be prepared using commercially available reagents (QIAseq miRNA Library kit). The quantification of miRNAs will be done by the Qubit dsDNA HS assay kit in the Qubit fluorometer before the cDNA library generation.Statistical analyses of differentially expressed miRNAs will be carried out using EdgeR by the generalized linear model. Fold changes of differentially-expressed microRNA will be measured in log2 scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of aspirated thrombus burden</measure>
    <time_frame>12 months</time_frame>
    <description>The volume of aspirated thrombi will be quantified (in mm3) using micro-CT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression and post-procedural Thrombolysis in Myocardial Infarction (TIMI) flow</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale as described above) will be correlated to post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression (measured in log2 scale) with distal embolization</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale, as described above) will be correlated to distal embolization (dichotomous variable-yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNAs expression and volume of aspirated thrombus.</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNA (measured in log2 scale) will be correlated to the volume of aspirated thrombi (measured in mm3), as it will be quantified using micro-CT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association between fold changes of microRNA expression and Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)</measure>
    <time_frame>12 months</time_frame>
    <description>Fold changes of differentially-expressed microRNAs (measured in log2 scale) will be correlated to MACCE. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Thrombi</condition>
  <condition>MicroRNA</condition>
  <arm_group>
    <arm_group_label>patients with low thrombus burden</arm_group_label>
    <description>patients with the lower volume of aspirated thrombi, as measured using micro-CT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with high thrombus burden</arm_group_label>
    <description>patients with the higher volume of aspirated thrombi, as measured using micro-CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thrombus aspiration</intervention_name>
    <description>Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.</description>
    <arm_group_label>patients with high thrombus burden</arm_group_label>
    <arm_group_label>patients with low thrombus burden</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Intracoronary blood samples will be collected (during thrombus aspiration) along with&#xD;
      peripheral blood samples and will be analyzed for the presence of specific micro-RNAs.&#xD;
&#xD;
      The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using&#xD;
      the Micro/Nano-CT.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        210 consecutive patients presenting with STEMI and undergoing thrombus aspiration will be&#xD;
        enrolled in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with symptoms of myocardial ischemia lasting for more than 30 minutes&#xD;
&#xD;
          -  Definite ECG changes indicating STEMI&#xD;
&#xD;
          -  Patients undergoing primary PCI within 12 hours from symptom onset&#xD;
&#xD;
          -  Possibility to perform thrombus aspiration&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with fibrinolytic therapy for qualifying index STEMI event&#xD;
&#xD;
          -  Patients with known intolerance to aspirin, ticagrelor or heparin&#xD;
&#xD;
          -  Patients with active internal bleeding&#xD;
&#xD;
          -  Patients with a recent history of intracranial hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Sianos</last_name>
    <role>Study Chair</role>
    <affiliation>Associate Professor of Cardiology, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Vizirianakis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitrios Fatouros</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor in Pharmaceutical Technology , Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eleftherios Angelis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor in Statistics, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Arvanitidis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Research, Hellenic Center for Marine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Michaelson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Pathology, Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Zacharopoulos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post-Doctoral Fellow, Hellenic Center for Marine Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Ouzounis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Research, Centre for Research and Technology Hellas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Efstratios Karagiannidis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phd Candidate, Aristotle University of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. doi: 10.1016/j.jacc.2007.04.059. Epub 2007 Jul 30.</citation>
    <PMID>17692740</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393. No abstract available.</citation>
    <PMID>28886621</PMID>
  </reference>
  <reference>
    <citation>Grover SP, Saha P, Jenkins J, Mukkavilli A, Lyons OT, Patel AS, Sunassee K, Modarai B, Smith A. Quantification of experimental venous thrombus resolution by longitudinal nanogold-enhanced micro-computed tomography. Thromb Res. 2015 Dec;136(6):1285-90. doi: 10.1016/j.thromres.2015.10.006. Epub 2015 Oct 9.</citation>
    <PMID>26489729</PMID>
  </reference>
  <reference>
    <citation>Vorpahl M, Foerst JR, Kelm M, Kaplan AV, Virmani R, Ball T. The complementary role of microCT and histopathology in characterizing the natural history of stented arteries. Expert Rev Cardiovasc Ther. 2011 Jul;9(7):939-48. doi: 10.1586/erc.11.81.</citation>
    <PMID>21809975</PMID>
  </reference>
  <reference>
    <citation>Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008 Oct;18(10):997-1006. doi: 10.1038/cr.2008.282.</citation>
    <PMID>18766170</PMID>
  </reference>
  <reference>
    <citation>Navickas R, Gal D, Laucevicius A, Taparauskaite A, Zdanyte M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016 Sep;111(4):322-37. doi: 10.1093/cvr/cvw174. Epub 2016 Jun 29.</citation>
    <PMID>27357636</PMID>
  </reference>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>February 16, 2022</last_update_submitted>
  <last_update_submitted_qc>February 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Karagiannidis Efstratios</investigator_full_name>
    <investigator_title>Medical Doctor (resident physician, Cardiology Department, AHEPA University hospital), PhD candidate, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bioprinting</keyword>
  <keyword>thrombus aspiration</keyword>
  <keyword>micro-CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03832153
org study id: 20181028
nct id: NCT03832153
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Acute myocardial infarction with ST elevation (STEMI) is one of the leading causes of
      mortality. Although the presence of thrombus in STEMI patients has been linked to adverse
      outcomes, routine thrombus aspiration has not been proven effective. A potential explanation
      could be that patients with STEMI should be risk-stratified. Thus, a more personalized
      approach in treating these patients is stressfully required. This proposal aims to establish
      the required interdisciplinary infrastructure for developing a risk-stratification model by
      implementing clinical, laboratory and angiographic data with molecular knowledge obtained by
      using innovative technologies, such as data from nano/micro-Computed tomography and
      circulating microRNAs. Two hundred consecutive patients with STEMI undergoing thrombus
      aspiration will be enrolled in the study and will be followed-up for one year for Major
      Adverse Cardiac and Cerebrovascular events (MACCE). The proposed approach will shed light on
      the pathophysiological mechanisms and broaden the investigator's understanding of the complex
      cellular and molecular interactions in the STEMI setting that, along with clinical
      parameters, affect patient outcomes. Furthermore, it will enable the identification of
      certain circulating micro-RNAs as cardiovascular disease biomarkers and it will help
      clinicians to better stratify the cardiovascular and cerebrovascular risk of patients with
      STEMI. As part of the work, important characteristics of aspirated thrombi will be assessed
      for the first time (such as volume, density and shape) and will be linked to patient
      outcomes. All this information will be incorporated into one in-vitro model, which will be
      developed using bioprinting and microfluidics methodologies. The in-vitro model will
      facilitate: (i) the in-depth exploration of the pathophysiological mechanisms in patients
      with STEMI; and (ii) the therapeutic optimization of innovative nanocarriers/nanomedicines
      with thrombolytic efficacy. Clearly, the study improves personalized cardiovascular medicine
      approaches, by considering individual patient clinical assessment in a way that empowers the
      precision in diagnosis and therapy.
observational model: Case-Only
time perspective: Prospective
measure: Fold changes of differentially-expressed microRNA from peripheral blood from patients suffering from STEMI (measured in log2 scale)
time frame: 12 months
description: The expression profiles of the total number of microRNAs that exist in the peripheral blood of patients suffering from STEMI will be analyzed using Next Generation Sequencing (NGS). Blood samples collected from the patients will be used to extract microRNAs through the application of suitable microRNA isolation kit (miRNeasy Serum/Plasma kit). Following, the miRNA library construction will be prepared using commercially available reagents (QIAseq miRNA Library kit). The quantification of miRNAs will be done by the Qubit dsDNA HS assay kit in the Qubit fluorometer before the cDNA library generation.Statistical analyses of differentially expressed miRNAs will be carried out using EdgeR by the generalized linear model. Fold changes of differentially-expressed microRNA will be measured in log2 scale.
measure: Volume of aspirated thrombus burden
time frame: 12 months
description: The volume of aspirated thrombi will be quantified (in mm3) using micro-CT.
measure: Association between fold changes of microRNA expression and post-procedural Thrombolysis in Myocardial Infarction (TIMI) flow
time frame: 12 months
description: Fold changes of differentially-expressed microRNAs (measured in log2 scale as described above) will be correlated to post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3).
measure: Association between fold changes of microRNA expression (measured in log2 scale) with distal embolization
time frame: 12 months
description: Fold changes of differentially-expressed microRNAs (measured in log2 scale, as described above) will be correlated to distal embolization (dichotomous variable-yes/no).
measure: Association between fold changes of microRNAs expression and volume of aspirated thrombus.
time frame: 12 months
description: Fold changes of differentially-expressed microRNA (measured in log2 scale) will be correlated to the volume of aspirated thrombi (measured in mm3), as it will be quantified using micro-CT.
measure: Association between fold changes of microRNA expression and Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
time frame: 12 months
description: Fold changes of differentially-expressed microRNAs (measured in log2 scale) will be correlated to MACCE. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
arm group label: patients with low thrombus burden
description: patients with the lower volume of aspirated thrombi, as measured using micro-CT
arm group label: patients with high thrombus burden
description: patients with the higher volume of aspirated thrombi, as measured using micro-CT
intervention type: Procedure
intervention name: thrombus aspiration
description: Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
arm group label: patients with high thrombus burden
arm group label: patients with low thrombus burden
Intracoronary blood samples will be collected (during thrombus aspiration) along with
      peripheral blood samples and will be analyzed for the presence of specific micro-RNAs.

      The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using
      the Micro/Nano-CT.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Georgios Sianos
role: Study Chair
affiliation: Associate Professor of Cardiology, Aristotle University of Thessaloniki
last name: Ioannis Vizirianakis
role: Principal Investigator
affiliation: Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
last name: Dimitrios Fatouros
role: Principal Investigator
affiliation: Associate Professor in Pharmaceutical Technology , Aristotle University of Thessaloniki
last name: Eleftherios Angelis
role: Principal Investigator
affiliation: Professor in Statistics, Aristotle University of Thessaloniki
last name: Christos Arvanitidis
role: Principal Investigator
affiliation: Director of Research, Hellenic Center for Marine Research
last name: James Michaelson
role: Principal Investigator
affiliation: Associate Professor, Department of Pathology, Harvard Medical School
last name: Athanasios Zacharopoulos
role: Principal Investigator
affiliation: Post-Doctoral Fellow, Hellenic Center for Marine Research
last name: Christos Ouzounis
role: Principal Investigator
affiliation: Director of Research, Centre for Research and Technology Hellas
last name: Efstratios Karagiannidis
role: Principal Investigator
affiliation: Phd Candidate, Aristotle University of Thessaloniki
facility: 
country: Greece
citation: Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007 Aug 14;50(7):573-83. doi: 10.1016/j.jacc.2007.04.059. Epub 2007 Jul 30.
PMID: 17692740
citation: Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393. No abstract available.
PMID: 28886621
citation: Grover SP, Saha P, Jenkins J, Mukkavilli A, Lyons OT, Patel AS, Sunassee K, Modarai B, Smith A. Quantification of experimental venous thrombus resolution by longitudinal nanogold-enhanced micro-computed tomography. Thromb Res. 2015 Dec;136(6):1285-90. doi: 10.1016/j.thromres.2015.10.006. Epub 2015 Oct 9.
PMID: 26489729
citation: Vorpahl M, Foerst JR, Kelm M, Kaplan AV, Virmani R, Ball T. The complementary role of microCT and histopathology in characterizing the natural history of stented arteries. Expert Rev Cardiovasc Ther. 2011 Jul;9(7):939-48. doi: 10.1586/erc.11.81.
PMID: 21809975
citation: Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008 Oct;18(10):997-1006. doi: 10.1038/cr.2008.282.
PMID: 18766170
citation: Navickas R, Gal D, Laucevicius A, Taparauskaite A, Zdanyte M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016 Sep;111(4):322-37. doi: 10.1093/cvr/cvw174. Epub 2016 Jun 29.
PMID: 27357636
responsible party type: Principal Investigator
investigator affiliation: Aristotle University Of Thessaloniki
investigator full name: Karagiannidis Efstratios
investigator title: Medical Doctor (resident physician, Cardiology Department, AHEPA University hospital), PhD candidate, Principal Investigator
mesh term: Myocardial Infarction
mesh term: Acute Coronary Syndrome
mesh term: ST Elevation Myocardial Infarction
mesh term: Thrombosis
mesh term: Infarction